SYNDAX PHARMACEUTICALS INC's ticker is SNDX and the CUSIP is 87164F105. A total of 57 filers reported holding SYNDAX PHARMACEUTICALS INC in Q4 2016. The put-call ratio across all filers is - and the average weighting 0.2%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q1 2019 | $528,000 | +73.1% | 100,555 | +46.8% | 0.00% | – |
| Q4 2018 | $305,000 | -43.3% | 68,512 | +2.8% | 0.00% | – |
| Q3 2018 | $538,000 | +157.4% | 66,624 | +123.5% | 0.00% | – |
| Q2 2018 | $209,000 | -85.0% | 29,809 | -69.6% | 0.00% | -100.0% |
| Q1 2018 | $1,395,000 | +198.1% | 98,039 | +83.6% | 0.00% | – |
| Q4 2017 | $468,000 | -20.1% | 53,384 | +6.6% | 0.00% | – |
| Q3 2017 | $586,000 | -15.2% | 50,080 | +1.2% | 0.00% | – |
| Q2 2017 | $691,000 | +119.4% | 49,484 | +115.9% | 0.00% | – |
| Q1 2017 | $315,000 | +160.3% | 22,924 | +36.2% | 0.00% | – |
| Q4 2016 | $121,000 | -25.8% | 16,833 | +56.4% | 0.00% | – |
| Q3 2016 | $163,000 | +46.8% | 10,760 | -4.8% | 0.00% | – |
| Q2 2016 | $111,000 | – | 11,299 | – | 0.00% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Aisling Capital Management LP | 1,025,000 | $24,631,000 | 16.36% |
| Kynam Capital Management, LP | 2,272,915 | $54,618,000 | 11.51% |
| Frazier Life Sciences Management, L.P. | 3,412,838 | $82,010,000 | 6.32% |
| Foresite Capital Management IV, LLC | 690,000 | $16,581,000 | 5.33% |
| Paradigm Biocapital Advisors LP | 1,085,142 | $26,076,000 | 3.48% |
| ACUTA CAPITAL PARTNERS, LLC | 324,614 | $7,800,000 | 3.36% |
| COMMODORE CAPITAL LP | 738,110 | $17,737,000 | 2.85% |
| SPHERA FUNDS MANAGEMENT LTD. | 822,696 | $19,769,000 | 2.74% |
| Avidity Partners Management LP | 5,586,900 | $134,253,000 | 2.73% |
| HealthCor Management, L.P. | 859,240 | $20,648,000 | 2.58% |